Group 1 - The core business of Lidman includes research, production, sales, and service of in vitro diagnostic reagents, diagnostic instruments, and biochemical raw materials [1] - The company has received multiple accolades, including "National High-tech Enterprise" and "Beijing Specialized and Innovative Enterprise" [1] - As of the first quarter of 2025, Lidman reported a revenue of 78.91 million yuan, a year-on-year decrease of 16.61%, and a net profit of -1.25 million yuan, a year-on-year increase of 53.73% [1] Group 2 - The latest closing price of Lidman was 5.22 yuan, with a market capitalization of 2.84 billion yuan and a price-to-book ratio of 1.71, marking a new low in 79 days [1] - The company is held by three institutions, with a total holding of 263.08 million shares valued at 1.24 billion yuan [1] - The industry average price-to-earnings ratio (PE) is 50.99, while Lidman's PE (TTM) is -38.56, indicating a significant divergence from industry norms [2]

证券代码：300289 证券简称：利德曼 公告编号：2025-026 北京利德曼生化股份有限公司 关于子公司重新签订房屋租赁合同暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、关联交易概述 1、北京利德曼生化股份有限公司（以下简称"公司"）全资子公司广 州利德曼医疗科技有限公司（简称"广州利德曼"）于 2021 年 3 月 1 日与 广州开发区控股集团有限公司（简称"广开控股"）签订《房屋租赁合同》， 并与广州凯云智慧服务有限公司（简称"凯云服务"）签订了《物业管理 服务合同》，内容详见公司在巨潮资讯网（http://www.cninfo.com.cn）披 露的《关于全资子公司重新签订房屋租赁合同暨关联交易的公告》（公告 编号：2021-019）以及后续披露的《关于重新审议全资子公司房屋租赁 暨关联交易的公告》（公告编号：2024-007）。 2、根据所在园区最新的租赁政策，广州利德曼于近日与广开控股重 新签订《房屋租赁合同》，与广开控股委托的物业管理服务公司广州凯云 发展股份有限公司（简称"凯云发展"）签订《加速器园区管理服务合同》。 ...

Core Viewpoint - Lidman Biochemical Co., Ltd. is experiencing a decline in revenue and profit, with a significant net outflow of funds, indicating potential challenges in the market [1][2]. Company Overview - Lidman specializes in the research, production, sales, and service of in vitro diagnostic reagents, diagnostic instruments, and biochemical raw materials [1]. - The company's main products include biochemical diagnostic reagents, immunodiagnostic reagents, and automated chemiluminescence immunoassay analyzers [1]. - Lidman has received multiple accolades, including "National High-tech Enterprise" and "Beijing Specialized and Innovative Enterprise" [1]. Financial Performance - For Q1 2025, Lidman reported revenue of 78.91 million yuan, a year-on-year decrease of 16.61% [1]. - The net profit for the same period was -1.25 million yuan, reflecting a year-on-year increase in losses of 53.73% [1]. - The gross profit margin stood at 53.56% [1]. Market Position - As of May 27, Lidman's stock closed at 4.98 yuan, with a market capitalization of 2.709 billion yuan and a price-to-book ratio of 1.63 [1]. - The company has seen a net outflow of 3.4978 million yuan in principal funds on May 27, with a total outflow of 7.7543 million yuan over the past five days [1]. Industry Comparison - Lidman's PE (TTM) ratio is -36.79, while the industry average is 49.11, indicating a significant disparity in valuation metrics [2]. - The industry median PE (TTM) is 35.89, suggesting that Lidman is underperforming compared to its peers [2].

Group 1 - The core viewpoint of the news is that Lidman Biochemical Co., Ltd. is experiencing a decline in revenue and profit, with a significant drop in stock performance and net outflow of funds [1] - As of May 20, Lidman’s stock closed at 5.04 yuan, up 1.61%, with a latest price-to-book ratio of 1.65, marking a 40-day low and a total market capitalization of 2.742 billion yuan [1] - In terms of fund flow, on May 20, Lidman saw a net outflow of 3.714 million yuan, with a total outflow of 7.288 million yuan over the past five days [1] Group 2 - The main business of Lidman includes research, production, sales, and service of in vitro diagnostic reagents, diagnostic instruments, and biochemical raw materials [1] - The company’s key products consist of biochemical diagnostic reagents, immunodiagnostic reagents, and automated chemiluminescence immunoassay analyzers [1] - Recent performance data shows that in Q1 2025, Lidman achieved operating revenue of 78.9087 million yuan, a year-on-year decrease of 16.61%, and a net profit of -1.25172554 million yuan, a year-on-year decline of 53.73%, with a gross profit margin of 53.56% [1] Group 3 - Lidman has received multiple accolades, including "National High-tech Enterprise," "Zhongguancun High-tech Enterprise," and recognition as a leading enterprise in the "G20 Project" for the Beijing biopharmaceutical industry [1] - The company was also recognized as a "Benchmark Enterprise in Intelligent Manufacturing" in Beijing for 2018 and received certification for "Digital Workshop" in 2022 [1]

Group 1 - The core viewpoint of the news is that Lidman Biochemical Co., Ltd. is experiencing a decline in revenue and profit, with a significant drop in stock price and market performance [1] - As of April 29, Lidman closed at 4.6 yuan, up 2.00%, with a latest price-to-book ratio of 1.51, marking a new low in 18 days, and a total market value of 2.502 billion yuan [1] - In terms of capital flow, on April 29, Lidman saw a net outflow of 2.7495 million yuan, with a total outflow of 1.6919 million yuan over the past five days [1] Group 2 - The main business of Lidman includes research, production, sales, and service of in vitro diagnostic reagents, diagnostic instruments, and biochemical raw materials [1] - The company's key products consist of biochemical diagnostic reagents, immunodiagnostic reagents, and automated chemiluminescence immunoassay analyzers [1] - Recent performance data shows that in Q1 2025, the company achieved operating revenue of 78.9087 million yuan, a year-on-year decrease of 16.61%, and a net profit of -1,251,725.54 yuan, a year-on-year decline of 53.73%, with a gross profit margin of 53.56% [1] Group 3 - Lidman has received several accolades, including "National High-tech Enterprise," "Zhongguancun High-tech Enterprise," and recognition as a leading enterprise in the "G20 Project" for the Beijing biopharmaceutical industry [1] - The company was also recognized as a "Benchmark Enterprise in Intelligent Manufacturing" in Beijing for 2018 and received certification for "Digital Workshop" in 2022 [1] Group 4 - In comparison to industry averages, Lidman's PE (TTM) is -33.98, and its price-to-book ratio is 1.51, while the industry average PE is 47.74 and the average price-to-book ratio is 4.40 [2] - The industry median PE is 36.15, with a median price-to-book ratio of 2.28, indicating that Lidman is underperforming relative to its peers [2]

证券代码：300289 证券简称：利德曼 公告编号：2025-023 北京利德曼生化股份有限公司 第六届监事会第四次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 北京利德曼生化股份有限公司（以下简称"公司"）第六届监事会 第四次会议于 2025 年 4 月 24 日在北京市北京经济技术开发区兴海路 5 号公司二层会议室以通讯方式召开。本次会议通知于 2025 年 4 月 17 日以电子邮件方式向全体监事发出，与会的各位监事已知悉与所 审议事项相关的必要信息。本次会议由公司监事会主席林冠宇先生主 持，应出席本次会议的监事 3 名，亲自出席监事 3 名。本次会议的召 集和召开符合《公司法》及《公司章程》等相关法律法规的规定。经 全体监事审议，投票表决通过以下议案： 一、审议通过《关于公司 2025 年第一季度报告的议案》 北京利德曼生化股份有限公司 监 事 会 2025 年 4 月 24 日 监事会对公司 2025 年第一季度报告进行了审核，提出如下书面 审核意见：公司董事会编制和审议公司《2025 年第一季度报告》的 程序符合法律法规、中国证监会 ...

具体内容详见公司在巨潮资讯网(http://www.cninfo.com.cn)披露的 《2025 年第一季度报告》（公告编号：2025-024）。 证券代码：300289 证券简称：利德曼 公告编号：2025-022 北京利德曼生化股份有限公司 第六届董事会第四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 北京利德曼生化股份有限公司(以下简称"公司")第六届董事会第四 次会议于 2025 年 4 月 24 日在北京市北京经济技术开发区兴海路 5 号公 司二层会议室以通讯方式召开。本次会议通知于 2025 年 4 月 17 日以电 子邮件方式送达全体董事，与会的各位董事已知悉与所审议事项相关的 必要信息。本次会议由董事长尧子女士主持，应出席本次会议的董事 7 名，亲自出席会议的董事 7 名。公司监事和高级管理人员列席了本次会 议。本次会议的召集和召开符合《公司法》和《公司章程》等有关规定， 会议所形成的有关决议合法、有效。经全体董事审议，投票表决通过如 下议案： 一、审议通过《关于公司 2025 年第一季度报告的议案》 董事会认为公司 202 ...

Revenue and Profitability - The company's revenue for Q1 2025 was ¥78,908,717.94, a decrease of 16.61% compared to ¥94,624,115.26 in the same period last year[4] - The net profit attributable to shareholders was -¥1,251,725.54, an improvement of 53.73% from -¥2,705,087.82 year-on-year[4] - Total operating revenue for the current period was ¥78,908,717.94, a decrease of 16.67% from ¥94,624,115.26 in the previous period[25] - Net profit for the current period was -¥914,987.98, an improvement from -¥1,957,415.15 in the previous period[26] - The company reported a basic and diluted earnings per share of -¥0.0023, compared to -¥0.0050 in the previous period[27] Cash Flow - The net cash flow from operating activities increased by 25.64% to ¥10,694,966.12, compared to ¥8,512,332.16 in the previous year[4] - Cash inflow from operating activities totaled ¥101,923,589.67, down from ¥130,917,998.72 in the previous period[29] - Total cash outflow from operating activities was 91,228,623.55, compared to 122,405,666.56 previously[30] - Cash paid for purchasing goods and services was ¥39,042,060.36, a decrease from ¥48,264,573.37 in the previous period[29] - Cash inflow from investment activities totaled 280,434,784.09, compared to 181,097,027.40 previously[30] - Net cash flow from investment activities was -74,867,448.91, a significant decrease from 163,290,894.40 in the prior period[30] - Cash received from investment recoveries was 279,000,000.00, up from 180,000,000.00 in the previous period[30] - Cash paid for the acquisition of fixed assets was 1,302,233.00, significantly lower than 17,806,133.00 previously[30] - The net increase in cash and cash equivalents was -65,269,708.16, contrasting with an increase of 171,619,204.11 in the previous period[30] - The ending balance of cash and cash equivalents was 505,749,676.17, down from 736,108,262.72[30] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,810,631,174.12, a decrease of 0.65% from ¥1,822,421,427.54 at the end of the previous year[4] - Total current assets amount to 1,107,411,911.83 RMB, slightly increased from 1,107,151,616.89 RMB at the beginning of the period[22] - Total liabilities decreased to ¥92,963,266.93 from ¥103,838,532.38 in the previous period[24] - Total liabilities include accounts payable of 12,441,916.21 RMB, down from 19,789,100.92 RMB, a decrease of approximately 37.1%[22] - The total equity attributable to shareholders was ¥1,660,848,895.85, a slight decrease of 0.08% from ¥1,662,100,621.39 at the end of the previous year[4] Financial Performance - The weighted average return on net assets was -0.08%, improving from -0.16% in the same period last year[4] - The company reported a financial expense of -¥1,065,029.71, an improvement from -¥2,774,498.86 in the previous period[26] - The company reported a significant increase in financial expenses, which decreased by 61.62% to -¥1,064,939.39 compared to -¥2,774,498.86 last year[12] - Investment income showed a decline of 118.94%, resulting in a loss of -¥53,398.96 compared to a profit of ¥281,974.93 in the previous year[12] Shareholder Information - Total number of common shareholders at the end of the reporting period is 17,525[17] - The largest shareholder, Guangzhou High-tech Zone Technology Holdings Group Co., Ltd., holds 46.35% of shares, totaling 252,133,152 shares[17] - The total equity attributable to shareholders of the parent company was ¥1,660,848,895.85, slightly down from ¥1,662,100,621.39 in the previous period[24] Other Information - The company has no preferred shareholders or related changes in preferred stock ownership[18] - The company has not reported any changes in restricted shares during the period[20] - There are no significant new strategies or product developments mentioned in the conference call[21] - The company did not undergo an audit for the first quarter report[32]

关于申请银行综合授信额度的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 北京利德曼生化股份有限公司(以下简称"公司")于 2025 年 4 月 24 日召开第六届董事会第四次会议，审议通过了《关于申请银行综合授 信额度的议案》，董事会同意公司向招商银行股份有限公司北京分行 申请壹亿元的综合授信额度，最终以银行实际审批的授信额度为准， 授信期限为一年，具体起止日期以银行实际审批为准。授信额度不等 于公司的融资金额，实际融资金额在授信额度内以银行与公司实际发 生的融资金额为准。董事会授权公司董事长或其指定的授权代理人办 理上述授信额度申请事宜，并签署相关法律文件，董事会决议有效期 一年。 本次授信属于公司董事会有权决定的一般事项，无需提交股东大 会审批。 证券代码：300289 证券简称：利德曼 公告编号：2025-025 北京利德曼生化股份有限公司 特此公告。 北京利德曼生化股份有限公司 董 事 会 2025 年 4 月 24 日 ...

北京大成律师事务所 关于北京利德曼生化股份有限公司 2024 年年度股东大会的 法 律 意 见 书 大成证字[2025]第[11]号 北 京 大 成 律 师 事 务 所 www.dentons.cn 北京市朝阳区朝阳门南大街 10 号兆泰国际中心 B 座 16-21 层（100020） 16-21/F, Tower B, ZT International Certer, No.10, Chaoyangmen South Road Chaoyang District, 100020, Beijing, China Tel: +86 10-58137799 Fax: +86 10-58137788 北京大成律师事务所 法律意见书 北京大成律师事务所 关于北京利德曼生化股份有限公司 2024 年年度股东大会的 法律意见书 大成证字[2025]第[11]号 1 北京大成律师事务所 法律意见书 发表的结论性意见合法、准确，不存在虚假记载、误导性陈述或者重大遗漏，并 承担相应法律责任。 本所律师根据《股东会规则》第六条的要求，按照律师行业公认的业务标准、 道德规范和勤勉尽责的精神，对本次股东大会所涉及的有关事项和相关文件 ...